2 Outline Overview of MS Acute treatment (relapse) Long term management MS and Lifestyle
3 MS (A brief overvveiw)Figure. A: RRMS is characterized by acute attacks with full recovery or with partial recovery. B: SPMS starts with a RR course followed by a progressive phase. C: PPMS is characterized by progression from onset of disease without acute relapses. D: PRMS is characterized by progression from onset of disease with acute relapses. Data from Lublin F, et al.
4 Pathogenesis of MS Lawrence Steinman & Scott Zamvil. Nature 2003 T cells, B cells and antigen-presenting cells (APCs), including macrophages, enter the central nervous system (CNS), where they secrete certain chemicals known as cytokines that damage the oligodendroglial cells. Lymphocytes diapedese into the CNS through use of a surface receptor known as alpha4-integrin. This step is impeded by antibodies specific for alpha4-integrin or by interferon-beta (IFN-beta). Once the blood–brain barrier is breached, other inflammatory cells accumulate in the white matter. Inside the brain, T cells and accompanying macrophages and microglial cells release osteopontin (OPN), interleukin-23 (IL-23), IFN-gamma and tumour-necrosis factor (TNF), all of which damage the myelin sheath. Also, the presence of OPN might lead to the attraction of T helper 1 (TH1) cells. T-cell activation can be blocked by altered peptide ligands (APLs), such as copaxone, or by statins. Concomitantly, B cells (plasma cells) produce myelin-specific antibodies, which interact with the terminal complex in the complement cascade to produce membrane-attack complexes that further damage oligodendroglial cells. DNA vaccination can be used to tolerize T- and B-cell responses to myelin.Lawrence Steinman & Scott Zamvil. Nature 2003
5 Good to know when talking about MS trials… EDSSMcDonald CriteriaPoser CriteriaDinner tomorrow?
6 EDSS (Expanded Disability Status Scale) EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory. EDSS steps 5.0 to 9.5 are defined by the impairment to ambulation. (FS = functional systems: cerebellar, bladder, brainstem, sensory, motor… )0.0: Normal Neurological Exam1.0: No disability, minimal signs on 1 FS2.0: Minimal disability in 1 of 7 FS3.0: Moderate disability in 1 FS; or mild disability in FS, though fully ambulatory4.0: Fully ambulatory without aid, up and about 12hrs a day despite relatively severe disability. Able to walk without aid 500 meters5.0: Ambulatory without aid for about 200 meters. Disability impairs full daily activities6.0: Intermittent or unilateral constant assistance (cane, crutch or brace) required to walk 100 meters with or without resting7.0: Unable to walk beyond 5 meters even with aid, essentially restricted to wheelchair, wheels self, transfers alone; active in wheelchair about 12 hours a day8.0: Essentially restricted to bed, chair, or wheelchair, but may be out of bed much of day; retains self care functions, generally effective use of arms9.0: Helpless bed patient, can communicate and eat10.0: Death due to MSKurtzke JF. Neurology. 1983; 33:
7 McDonald Criteria Origianlly devised in 2001 by Dr. Ian McDonald. They made use of MRI, and were intended to replace old Poser and Schumacher criteria.Recent update and change to criteria in 2010 (out of criticism that non-caucasion pts did not fit the origincal criteria
8 A Historical note: Poser Criteria Replaced Shumaker criteria for diagnosis of MS.Clinically definite MS2 attacks and clinical evidence of 2 separate lesions2 attacks, clinical evidence of one and paraclinical evidence of another separate lesionLaboratory supported Definite MS2 attacks, either clinical or paraclinical evidence of 1 lesion, and cerebrospinal fluid (CSF) immunologic abnormalities1 attack, clinical evidence of 2 separate lesions & CSF abnormalities1 attack, clinical evidence of 1 and paraclinical evidence of another separate lesion, and CSF abnormalitiesClinically probable MS2 attacks and clinical evidence of 1 lesion1 attack and clinical evidence of 2 separate lesions1 attack, clinical evidence of 1 lesion, and paraclinical evidence of another separate lesionLaboratory supported probable MS2 attacks and CSF abnormalitiesSCHUMACKER et al. Ann N Y Acad Sci Mar 31;122:552–568Poser CM, Paty DW, Scheinberg L, et al. (March 1983). Annals of Neurology 13 (3): 227–31
10 Treatment of the acute attack History:First RCT in 1970’s: adrenocorticotropic hormone (ACTH) was given IM. (Rose et al, 1970)n~200Shortened recovery time, but 4 weeks post treatment there was no clinical difference.Prominent SE’s (Na retention, hyperglycemia, Psych disorders) was what prompted trials of synthetic corticosteroids with a short half life.1992: Several RCTs emerged with methylprednisolone (but the duration and dose of treatment varied from 500mg IV QD x 3days to 1000mg IV QD x 10 days. Some trials showed benefit of PO methylprednisolone (500mg PO QD x 5d) (Meyers 1992, medlink)
11 Current Protocol?MOST COMMON CURRENT PROTOCOL: 3-7day course of IV methylprednisolone ( mg IV QD) with OR without a short taperMethyprednisolone reduced the risk of worsening or not improving within 5 weeks. No long term benefits, however, just a quicker recovery.Why not PO glucocorticoids?Barnes, Lancet 1997: RCT, n~80 acute MS relapses:Methlprednisolone 48 mg PO x 7d, then 24mg PO x 7d, then 12mg PO x 7d.Vs. 1000mg IV methylpred x 3days.No statistical difference in EDSS at 4 weeks.The authors concluded that oral steroids was a better regime in terms of cost, pt preference….
12 So, why not PO steroids? The Optic Neuritis Treatment Trial (ONTT) 314 patients. Random assignment to:PO prednisone 1mg/kg/d x 14 days, with a 4 day taperIV methyprednisolone 250 QID x 3days, PO pred 1mg/kg/d x 11 days, four day taper.PO placebo x 14 daysPrimary outcome: visual acuity, contrast sensitivityIV methylpred accelerated recovery, but 1 year outcomes were the same.IV methypred reduced the risk of conversion to MS (7.5% vs and 16.7%Oral pred arm had a significantly higher 2 year risk of recurrent optic neuritis in both eyes (30% vs 13 and 16%). At 10 years this risk remained.Beck et al. Am J Ophthalmol. 2004
13 Steroids continuedOral regimes are often used for MS exacerbations without optic neuritis.No good theoretical evidence as to why PO glucocorticoids would do this.SE’s of short term IV methyprednisolone:Relatively fewMental status changesUnmasking of infectionGI disturbancesDecreased bone density if repeated Tx: yearly bone density scans recommended in pts with repeated treatments.
14 Other options for acute MS? PLEX: plasma exchange vs. plasmapheresis? The difference?Plasma exchange: removal of plasma and replacement with fluidsPlasmapheresis: the removal of plasma (aphaeresis is removal in greek)The two are often used synonymously in medical literature.Up to date uses them synonymously: (“Complications of therapeutic plasma exchange” article)Buskard, Can Med Assoc J. 1978
15 PLEXMay be beneficial in acute severe MS attacks that do not respond to glucocorticoids.One trial: 22 pts with CNS demyelinating disease (12 MS pts total) assigned to PLEX vs sham.Moderate to greater improvements (42% PLEX, 6% sham).A later trial: 116 MS pts: results were that PLEX led to faster improvement in exacerbations that sham. (Note: no long term benefits)This let the AAN to include PLEX into the guidelines for a possible adjunctive treatment of relapsing MS.Weiner, Neurology. 1989
17 InterferonsPharmacology: Cytokines that mediate antiviral, antiproliferative and immunomodulatory activities in response to viral infections and other biological inducers.Interferon beta binds to human cells, leads to ifn gene product production… exact mechanism not understood, but there are some ideas:Modulates plasma cell IgG synthesisDecreases antigen presentation in microgliaAnti inflammatory effects via T cells (regulates migration, downregulates adhesion molecules…
18 The Interferons History Landmark paper in the 1980’s (Jacobs et al, 1986) showed for the first time that interferon beta, when intrathecally administered, could improve MS exacerbations.In 1987 a trial of IV interferon gamma was performed (n=18). (Panitch et al).The results? A dramatic increase in the relapse rate of patients treated with interferon gamma!Yet the important discovery that activating the peripheral immune system with peripheral drug administration can change the course of a CNS disease.
19 History continuedThe first approved med by the FDA was interferon beta 1b in 1993.In double blind placebo studies, interferon beta 1b:Decreases relapses by 34% at 2 yearsDecreased T2 lesion burden at 5 yearsSlowed disease progressionThe IFNB Multiple Sclerosis Study Group. Neurology. Apr 1993;43(4):655-61
20 Interferon beta-1a Interferon beta 1a had similar efficacy: 301 patients initiallyExacerbation rate decreased 29%Disease progression was slowed (progression in 29% of patients on interferon vs 34% in the placebo group).Decrease in the mean MRI lesion volume and number of enhancing lesions.The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. Mar 1996;39(3):285-94Dosing? Evidence of Interferon Dose-response: European North American Comparative Efficacy (EVIDENCE) trialRelapses occurs less frequently with higher doses, and MRI lesions were reduced with higher dosesNeutralizing antibodies occurred more with higher doses, and this did affect the outcome in pts with neutralizing Abs.
21 Options for interferons: Brand (Generic Name)FrequencyRoute of DeliveryUsual DoseAvonex(interferon beta-1a)Once a weekIntramuscular (into the muscle) injection30 mcgBetaseron(interferon beta-1b)Every other daySubcutaneous (under the skin) injection250 mcgExtavia (interferon beta-1b)Rebif (interferon beta-1a)Three times a week44 mcg
22 Side Effects of Interferons SEBeta-1b every other dayOnce weekly beta-1a3x/week beta 1amanagementtolerabilityLocal Skin reactions85%15%46%Transient 50% dose reduction, or improve injection techniqueGoodFever49%23%35%Tylenol, NSAIDS, pentoxyphillineFlulike Sx.52%61%56%Leuko or thrombocytopenia40%8%20%Transient 50% dose reductionIncreased liver enzymes19%10%Good (disappear within months.
24 Other SE’s worth mentioning (that didn’t fit neatly into my table): Neutralizing antibodies to interferon beta (NAbs)May effect clinical and MRI efficacy.Whether or not NAbs are detrimental to initial treatment response is unclear (studies yield mixed results)NAbs have been more consistantly shown to have a detrimental effect in the long term (3-4 years)NAbs occur with a lower frequency in IM interferon 1A (2-6%).SubQ interferon beta 1a (12-25%)Interferon beta 1b (22-38%)
25 Monitoring guidelines: CBC, Chem7, LFTS at 1,3, and 6 months. TSH should be checked every 6 months if Hx. Thyroid dysfunctionPsych sx (depression, SI)Pregnancy testCXREKG
26 Glatiramer acetateCopaxone is a random polymer of four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine. The mixture is antigenically similar to myelin basic protein, a component of the myelin sheath of nerves
27 Glatiramer acetate (copolymer 1) Mechanism of action – unclear of the exact mechanism, but:Experimental models: binds to MCH molecules and competes with myelin antigens for their presentation to T cells.Induces T helper 2 type suppressor cells to the CNS, these cells express anti-inflammatory granules.
28 History:Benefits of Glatiramer acetate first established in a double blind trial of RRMS pts (n=251) (Johnson et al 1995)At two years, significantly lower relapse rate (29%)Slowed EDSS progressionNo MRI outcome in initial trial.Other studies, including a 2007 trial which showed similar results and a reduction of MRI activity –two doses were tested as well (20 and 40mg). The higher dose was more effective(Cohen et al, 2007)
29 SE’s of Copaxone: Frequency Management Tolerability Local skin reactions90%Transient, no treatmentGoodPain64%Erythema57%Pruritis38%Necrosis0%Lipoatrophy45%Systemic reactions15%Dyspnea13%Flushing8%Chest Pain10%Palpitations5%
30 Side effects Generally well tolerated Short lived skin reactions are most commonLocalized lipoatrophy has been reported in up to 45% of pts in some studies, mainly women.May occur within months of therapy.Disfiguring, permanent
33 Before I talk about Fingolimod, the following was stolen shamelessly from Medscape’s latest CME quiz on Oral MS treatment (An okay video, but sponsored by Novartis):
34 What factor(s) go into selecting the optimal therapy, both injectable and oral, for patients with RRMS?Efficacy, cost, convenience, monitoring, tolerability, and safetyBurden of therapySafety and efficacyCost, convenience, monitoring, tolerability, and safety
35 Answer:Efficacy, cost, convenience, monitoring, tolerability, and safety
36 Which of the following treatment approaches is best supported by a currently available evidence base in a patient with highly active RRMS who shows breakthrough disease after taking interferon-beta for 6 months?Switching to natalizumabSwitching to fingolimodContinuing with interferon-beta for another 6 months and then switching to fingolimodContinuing with interferon-beta until steroids can no longer control motor symptoms and then switching to either fingolimod or natalizumab
37 Answer: A wide body of evidence supports an early switch in RRMS to fingolimod in pt’s with highly active disease and show signs of disease progression while on interferon beta therapy. Little data is available on the benefits of switching to tysabri
38 For patients with no history of cardiovascular disease and who are considering starting fingolimod, guidelines from the European Medicines Agency (EMA) recommend that they should have their heart activity monitored:Before the first dose of fingolimod and continuously overnight after the first dosePeriodically during the first 6 weeks of therapyNever, only patients with a history of cardiovascular disease are at risk of cardiac side effectsBefore the first dose and continuously for at least the first 6 hours thereafter
39 Answer: The EMA (European Medicines Agency) recommends all patients starting fingolimod should have their heart activity monitored BEFORE the 1st dose, and continuously for 6 hours. EXTEND monitoring by 2 hours in pts whose HR is lowest 6h post first dose, or overnight if cardiac problems are clinically significant.
40 FingolimodAn Sphingosine 1-Phosphate (S1P)-receptor modulator, derived from a fungal metaboliteReduces circulating WBCs by sequestering lymphocytes in lymph nodes, preventing them from becoming active.Originally developed as an antirejection drug, not marketed for this. Now under investigation as a potential CHF/antiarrythmic med.
41 History: FREEDOMS trial N-1272, RRMS patients (0.5 or 1.25 mg PO QD) 24 months:The annual relapse rate was 0.18, 0.16, and 0.4 (0.4 was placebo).Incidence of serious infections was similar.Macular edema occurred in 7 pts on the high dose group.TRANSFORMS trialN = 1200, RRMS pts (0.5mg or 1.25mg PO QD vs interferon beta-1aRelapse rate lower in fingolimod group ( 0.2, 0.16 and 0.33)MRI favored fingolimodNo change in disease progressionMore serious adverse effects in fingolimod groups: (2 serious disseminated infection: 1 herpes, 1 VSV. 12 patients developed skin or breast ca, 19 developed bradycardia or AV block)
43 Monitoring: Before initiation: CBC, LFTs, EKG Optho exam Varicella serology and vaccination Hx. (Fingolimod should not be started one month after vaccinationDerm exam – r/o precancerous lesions
44 Monitoring: First dose; During Tx: BP, cardiac monitor x 6hr (exxtend for 2 more hours if lowest HR at 6hr post dose), and overnight if cardiac sx.During Tx:Avoid live vaccinesOptho exam at 3 mo, and routinely if diabetic or hx uveitisLFT follow upPulmonary Function tests if clinically indicated
45 Tysabri (Natalizumab) Tysabri is a monoclonal antibody directed against alpha 4 integrins, specifically the very late antigen 4 (VLA-4) and vascular-cell adhesion molecule 1 (VCAM-1) and lymphocyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1) interactions, respectivelyAlpha-4 integrin is expressed on the surface of inflammatory lymphocytes and monocytes and may play a critical role in adhesion to the vascular endothelium.
46 Mechanism of action and significance? Rituximab, Natalizumab, and Efalizamab all inhibit the lyphocytes from binding to the endothelium in a similar manner, and all three are associated with rare cases of PML.
47 Tysabri:Two key trials: AFFIRM and SENTINEL – results pooled in a 2011 review:Significantly reduced the risk of having a relapse during two years of Tx (57%)Reduced the risk of progression of sx (RR = 0.74)NNT to prevents one exacerbation in 2 years was 4.83% reduction in MRI plaquesIncreased proportion of relapse free patients (32%)
49 Side effects: Tysabri AFFIRM study ENTINEL study Flu-like syndrome 22% 24%Infections13%15%Allergic reactions7%--GI disorders8%12%Menstrual disorders5%18%Chest discomfort4.5%<1%Vertigo6%AnxietyTremor1%Depression19%21%Local Bleeding3%Insomnia17%PML
50 Clinical useAAN guidelines recommend Tysabri be reserved for selected RRMS pts who have failed therapies because of:Continued disease activityMedication intolerance (should try both interferons AND copaxone before determining treatment failure/intolerance)Aggressive initial disease course (debatable*)Not to be used with beta interferon or other immunosuppresants b/c of PML risk.Drug Holiday?NOT recommended (gr 2C evidence), but a reasonable option for pts who are more concerned about PML.
51 Monitoring on TysabriBefore initiating: Leukocyte counts, initial brain MRI, JC serology for risk stratificationClinical evaluations every 6 monthsMonitor for:hepatotoxicityhypersensitivity reactions 1hr post infusionConsider antibody testing to tysabri if drug holiday (higher risk of allergic rxn)US: tysabri can only be given in select centers. Manditory patient registry (US) with checklist that asks about PML symptoms.
52 MitoxantroneAn antineoplastic drug with long lasting immunosuppressive effects.Approved for both RRMS and progressive forms of MS (Note: in progressive MS other meds are otherwise used off label)AAN 2003 Guidelines: because of cardiac toxicity, and limited benefits in small trials, mitoxantrone should be limited to patients who have failed other therapies.
53 Side Effects: Frequency Management Tolerability Nausea 76% Give always FrequencyManagementTolerabilityNausea76%Give alwaysintravenous antiemeticsbefore infusionsGoodAlopecia61%Transient, no treatmentMenstrual disorders(secondary amenorrhea)60%(10%)(hormonal replacement)(may be irreversible)Urinary tract infection32%Antibiotics (check whiteblood cell count)Leukopenia(granulocytopenia)19%(6%)White blood cell count 3to 6 days before andevery 10 days afterinfusions (50% dosereduction in neutrophilcount less than 1500mm3
54 SEFrequencyManagementTolerabilityIncreased liver enzymes15%Usually transient, 50%dose reduction ifgreater than 5-foldbaselineGoodCardiac toxicity2%Echocardiogram every6 months or above 100mg cumulative dose;stop if left ventricularejection fraction dropsby 10% or below 50%May progress even after stopping treatmentAcute leukemiaExceptionalMay occur even after stopping treatment
55 Multiple other trials for disease modifying drugs with no evidence, or further evidence needed: AlemtuzumabAzathioprineCCSVI treatmentCladribineCyclophosphamideDaclizumabDalfampridineFumarateGlucocorticoids in combination therapyIntravenous immune globulinLaquinimodOcrelizumabRituximabStatinsStem cell transplantationTeriflunomide
56 Since the first disease modifying treatment came out in 1993, there are now 7 drugs that are FDA approved for use in MSBrand (Generic Name)FrequencyRoute of DeliveryUsual DoseAvonex® (interferon beta-1a)Once a weekIntramuscular (into the muscle) injection30 mcgBetaseron® (interferon beta-1b)Every other daySubcutaneous (under the skin) injection250 mcgCopaxone® (glatiramer acetate)Every day20 mg (20,000 mcg)Extavia® (interferon beta-1b)Gilenya™ (fingolimod)Capsule taken orally0.5 mgRebif® (interferon beta-1a)Three times a week44 mcgTysabri® (natalizumab)Every four weeksIV infusion in a registered infusion facility300 mg
57 Manufacturer/Distributor & Year of Health Canada Approval Avonex® Biogen Idec Canada — 1998 Betaseron® Bayer HealthCare Pharmaceuticals, Inc. — 1995 Copaxone® Teva Neuroscience — 1997 Extavia® Novartis Pharmaceuticals Canada Inc. — 2009 Gilenya® Novartis Pharmaceuticals Canada Inc. — 2011 Rebif® EMD Serono Canada Inc. — 1998 Tysabri® Biogen Idec Canada Inc. — 2006
58 For interest’s sake: How much would you guess MS drug treatment costs per year, in Canada?
59 From MS Society Canada: Cost of disease modifying therapy: $20,000-$40,000 (dependant on the drug, the pharmacy, etc)The amount of reimbursement varies between provinces.
61 MS and Lifestyle Diet – no recommendations Vitamin D: Exercise ? Linked to decreased incidence of MSIU vitamin D/day for people who may be vit D deficient.ExerciseReduces fatigue, improved bladder and bowel function, strength and mood.AcupunctureStudies suggesting benefit, not cosidered to be a CAM to avoidMS Society Canada (2012)
62 Controversy and new directions Surgeons look over a balloon at the end of the wire, which is put through with a surgical catheter into the patient as part of MS treatment.(JOHN LEHMANN/THE GLOBE AND MAIL)
63 Commonly use CAM methods to avoid: Removal of amalgam fillingsSome suggestions that mercury in dental fillings can cause or trigger MS – No evidenceBee sting therapy24 week RCT showed no change in activity, disability or fatigue. No change in quality of life.MS Society Canada (2012)